MAP2K7 and melanoma: BRAF/MEK targeted therapies, such as dabrafenib and trametinib, have become the standard of care for the treatment of melanoma brain metastases with a BRAF-MEK pathway driver mutation [39] and currently have histology-agnostic approval for tumors harboring the BRAF V600E mutation.